US5674895A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dosage form comprising oxybutynin
Assignee: Alza Corp
•
Filing: 1995-05-22
•
Granted: 1997-10-07
•
Expires: 2015-05-22
Abstract
Abstract A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.
Inventors
- 👤 George V. Guittard
- 👤 Francisco Jao
- 👤 Susan M. Marks
- 👤 David J. Kidney
- 👤 Fernando Gumucio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 16:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K31/216; A61K31/22; A61K31/221; A61K9/0002; A61K9/0004; A61K9/2031; A61P; A61P13/00; A61P13/02; A61P13/10; A61P15/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
35 words
A therapeutic composition comprising: 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant.
Claim 2
Dependent Claim
35 words
A therapeutic composition comprising: 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant.
Claim 3
Dependent Claim
53 words
The therapeutic composition according to claim 1, wherein the oxybutynin is a therapeutically acceptable salt selected from the group consisting of acetate, bitartrate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hydrobromide, hydrochloride, lactate, malate, maleate, mandelate, mesylate, methylnitrate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, salicylate, stearate, succinate, sulfate, tannate, and tartrate.
Claim 4
Dependent Claim
86 words
A bilayered tablet comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 450 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose and 0.01 mg to 5 mg of a lubricant; in contact with a hydrogel layer comprising 40 mg to 250 mg of polyalkylene oxide, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.
Claim 5
Dependent Claim
86 words
A bilayered tablet comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 450 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose and 0.01 mg to 5 mg of a lubricant; in contact with a hydrogel layer comprising 40 mg to 250 mg of polyalkylene oxide, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.
Claim 6
Dependent Claim
100 words
A bilayered tablet comprising a therapeutic layer comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant; said layer in contact with a push layer comprising 40 mg to 250 mg of an alkali carboxymethylcellulose, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.1 mg to 30 mg of hydroxyalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.
Claim 7
Dependent Claim
100 words
A bilayered tablet comprising a therapeutic layer comprising a therapeutic layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 0.01 mg to 5 mg of a lubricant; said layer in contact with a push layer comprising 40 mg to 250 mg of an alkali carboxymethylcellulose, 10 mg to 50 mg of an osmagent, 0.1 mg to 20 mg of hydroxypropylalkylcellulose, 0.1 mg to 30 mg of hydroxyalkylcellulose, 0.0 ng to 1.5 mg of an antioxidant, and 0.2 mg to 7 mg of a lubricant.
Claim 8
Dependent Claim
117 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 1 mg to 50 mg of an osmagent; and contacting layer comprising 40 mg to 250 mg of an osmopolymer and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
Claim 9
Dependent Claim
117 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, and 1 mg to 50 mg of an osmagent; and contacting layer comprising 40 mg to 250 mg of an osmopolymer and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
Claim 10
Dependent Claim
118 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contacting displacement layer comprising 40 mg to 250 mg of carboxymethylcellulose and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
Claim 11
Dependent Claim
118 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contacting displacement layer comprising 40 mg to 250 mg of carboxymethylcellulose and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layers, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
Claim 12
Dependent Claim
120 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of a hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contracting displacement layer comprising 40 mg to 250 mg of polyalkylene oxide, and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layer, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
Claim 13
Dependent Claim
120 words
A delivery device for administering oxybutynin to a patient in need of oxybutynin, wherein the delivery device comprises: a drug layer comprising 1 ng to 450 mg of oxybutynin, 40 mg to 250 mg of polyalkylene oxide, 1 mg to 25 mg of a hydroxypropylalkylcellulose, 1 mg to 50 mg of an osmagent; and a contracting displacement layer comprising 40 mg to 250 mg of polyalkylene oxide, and 10 mg to 50 mg of an osmagent; a semipermeable wall that surrounds the layer, which semipermeable wall is permeable to the passage of fluid, and impermeable to the passage of oxybutynin, and an exit through the semipermeable wall for administering the oxybutynin to the patient at a controlled rate over time.
References Cited (Backward Citations)
US3845770A
Cited
US3916899A
Cited
US4088864A
Cited
US4063064A
Cited
US4111202A
Cited
US4285987A
Cited
US4327725A
Cited
US4612008A
Cited
US4783337A
Cited
US4800098A
Cited
US4863456A
Cited
US4824675A
Cited
US4816263A
Cited
US4902514A
Cited
US5399359A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-10-06 | 2001-04-07 | 2001-10-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-10-06 | 2005-04-07 | 2005-10-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-10-06 | 2009-04-07 | 2009-10-07 | $7700.00 | Window Closed / Lapsed |